RE: Clinical trial overhaul22 Mar 2023 07:40
From what Tim says it looks like the studies (Note plural) will stay in Oz:
"We have identified Australia as the ideal location for these studies for a number of reasons, including its thriving research and development ecosystem, diverse patient population, internationally recognised regulatory authorities and supportive R&D tax credits system. We are confident that Australia's regulatory process will enable us to move forward efficiently and effectively."
"See" you at the meeting. LH&K Mafuta